9th annual acute · virtual meeting. 14:05 - 15:40 session 4 - all chairs: dr. elias jabbour, md...
TRANSCRIPT
����������������������������������������������������������� ��������������������
�������� ������������������������������������������������������
COORDINATORS
www.mdanderson.es/cursoleucemia
#MadridLeukemia
ANNUAL ACUTE 9th
26th23rd SEPTEMBER 2020
VIRTUAL MEETING
14:05 - 15:40 SESSION 4 - ALL
Chairs: Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
14:05 - 14:25 First-line therapy of Ph-positive ALL: current status and perspectives Dr. Sabina Chiaretti, Sapienza University, Rome, Italy
14:25 - 14:45 Adult LAL: real-life treatment results Dr. Josep Mª Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain
14:45 - 15:05 Optimizing 1st line therapy based on MRD in ALL Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA
15:05 - 15:25 Case based discussion: Introducing new agents in day to day practice Dr. Claudio Cerchione, AOU Federico II, Naples, Italy
15:25 - 15:40 Discussion
15:40 - 15:55 Break
15:55 - 17:10 SESSION 5 - AML -1
Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
15:55 - 16:15 AML management ELN 2017 update Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany
16:15 - 16:35 Moving toward targeted approaches in AML Dr. Richard Stone, Dana-Farber Cancer Institute, Boston, USA
16:35 - 16:55 Update in Bcl2 inhibitors Dr. Daniel Pollyea, University of Colorado School of Medicine, USA
16:55 - 17:10 Discussion
17:10 - 17:25 Break
17:25 - 19:05 SESSION 6 - Immunotherapy
Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA
17:25 - 17:45 Immunotherapy in ALL Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA
17:45 - 18:05 Harnessing the immune system for threating AML Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA
18:05 - 18:25 CAR T: organization and start-up of a unit Dr. Manuel Guerreiro, Hospital Universitario y Politécnico La Fe. Valencia, Spain
18:25 - 18:45 CAR-T cell therapy in adult patients with ALL Dr. Nicolas Boissel, Hôpital Saint-Louis, Paris, France
18:45 - 19:05 Immunotherapy approaches in MDS Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
19:05 - 19:20 Discussion
09:30 - 11:05 SESSION 7 - AML-3
Chairs: Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
09:30 - 09:50 First line FLT3 AML Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy
09:50 - 10:10 Study of relapsed LAM Dr. Eva Barragán, Hospital Universitario y Politécnico La Fe, Valencia, Spain
10:10 - 10:30 Salvage therapy FLT-3 Dr. Jose�na Serrano, Hospital Universitario Reina Sofía, Córdoba, España
10:30 - 10:50 The challenge of starting maintenance after transplant Dr. Giovanni Martinelli, University of Bologna Policlinico S.Orsola-Malpighi, Bologna, Italy
10:50 - 11:05 Discussion
11:05 - 11:20 Break
11:20 - 13:55 SESSION 8 - AML-4. Session high risk
Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
11:20 - 11:40 Accurate diagnosis Dr. Jordi Esteve, Hospital Clinic, Barcelona, Spain
11:40 - 12:00 Goals not achieved in the Fit patient with AML. Decreasing mortality Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain
12:00 - 12:20 Current status of the transplant indication Dr. Jaime Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain
12:20 - 12:40 New formulations Dr. Raquel Sánchez, MD Anderson Cancer Center Madrid, Spain
12:40 - 13:00 New ways to deliver induction chemotherapy in AML Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain
13:00 - 13:20 Houston experience Dr. Guillermo Montalbán Bravo, MD Anderson Cancer Center, Houston, USA
13:20 - 13:40 UK experience TBC
13:40 - 13:55 Discussion
13:55 - 14:10 Break
14:10 - 15:40 SESSION 9 - COVID 19
Chairs: Dr. Josep Mª Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
14:10 - 14:30 COVID 19 Session: presentation Dr. Josep Mª Ribera, Josep Carreras Leukemia Research Institute, Barcelona, Spain
14:30 - 15:40 Discussion Dr. Jaime Sanz, Hospital Universitario y Politécnico La Fe, Valencia, Spain Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA Dr. Hartmut Döhner, Universitätsklinikum Ulm, Germany Dr. Breno Gusmão, Hospital Bene�cência Portuguesa, São Paulo, Brasil Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
15:40 - 15:50 Closing
FRIDAY, 25th SEPTEMBER 2020
WEDNESDAY, 23rd SEPTEMBER 2020
THURSDAY, 24th SEPTEMBER 2020
SATURDAY, 26th SEPTEMBER 2020
16:00 - 18:00 MEET THE EXPERT: CML Cases
Chairs: Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain
16:00 - 16:10 Welcome
16:10 - 17:25 SESSION 1 - Diagnostic
Chairs: Dr. Miguel Ángel Sanz, Hospital Universitario y Politécnico La Fe. Valencia, Spain Dr. Joaquín Sánchez, Hospital Reina Sofía, Córdoba, Spain
16:10 - 16:30 Impact of coexisting mutations and mechanisms of resistance to new agents Dr. Mª José Calasanz, CIMA LAB Diagnostics UNAV, Pamplona, Spain
16:30 - 16:50 Major altered signaling pathways in AML Dr. Joaquín Sánchez, Hospital Reina Sofía, Córdoba, Spain
16:50 - 17:10 MRD assessment and follow up Dr. Konstanze Döhner, Universitätsklinikum Ulm, Germany
17:10 - 17:25 Discussion
17:25 - 17:40 Break
17:40 - 19:15 SESSION 2 - Mieloid malignancies MDS & MF
Chairs: Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA TBC
19:40 - 18:00 CMML management Dr. Breno Gusmão, Hospital Bene�cência Portuguesa, São Paulo, Brasil
18:00 - 18:20 Management of lower risk MDS Dr. María Díez Campelo, Hospital Clínico Universitario de Salamanca, Spain
18:20 - 18:40 Prognostic and management of myelofibrosis patients that fail to conventional treatment Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain
18:40 - 19:00 Oral therapies in MDS Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA
19:00 - 19:15 Discussion
13:30 - 14:05 SESSION 3 - AML -2
13:30 - 13:50 Hope and future Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain
13:50 - 14:05 Discussion
26th23rd SEPTEMBER 2020 VIRTUAL MEETINGANNUAL ACUTE 9th
CREDITS
Continuing Education Credits requested to the Spanish National Health System.
With the collaboration of the Educational Committee of MD Anderson Cancer Center Madrid.
ORGANIZED BYSPONSORS
TECHNICAL SECRETARIAT
PLATINUM
GOLD
SILVER
COLLABORATOR
(+34) 91 372 02 03 [email protected]/cursoleucemia
www.servier.es